Bi-Coastal Pharmaceutical gains US marketing rights to xerostomia drug
The product is sold in a 40ml spray bottle that if used as directed is a two-month supply. Ralph Massa, Jr, Bi-Coastal Pharmaceutical’s president and COO, said: “I
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
The first study, conducted by the Gruppo Italiano Malattie Ematologiche dell Adulto (GIMEMA), is an ongoing, open-label, single-stage, multicenter Phase II clinical trial, designed to evaluate the therapeutic